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Abstract 
Background: The majority of cases of frontotemporal lobar degeneration (FTLD) are characterized by focal cor-
tical atrophy with an underlying tau or TDP-43 proteinopathy. A subset of FTLD cases, however, lack tau and 
TDP-43 immunoreactivity, but have neuronal inclusions positive for ubiquitin, referred to as atypical FTLD 
(aFTLD-U). Studies have demonstrated that ubiquitin-positive inclusions in aFTLD-U are immunoreactive for 
fused in sarcoma (FUS). As such, the current nosology for this entity is FTLD-FUS, which is thought to include 
not only aFTLD-U but also neuronal intermediate filament inclusion disease (NIFID) and basophilic inclusion 
body disease. 
Objective: To compare pathological features of cases of aFTLD-U and NIFID. 
Methods: We reviewed the neuropathology of 15 patients (10 males and 5 females; average age at death 54 
years (range 41-69 years)) with an antemortem clinical diagnosis of a frontotemporal dementia and pathologi-
cal diagnosis of aFTLD-U (n=8) or NIFID (n=7). Sections were processed for immunohistochemistry and immu-
noelectron microscopy with FUS, TDP-43, and α-internexin (αINX) antibodies. 
Results: Eight cases had pathologic features consistent with FTLD-FUS, with severe striatal atrophy (7/8 cases), 
as well as FUS-positive neuronal cytoplasmic and vermiform intranuclear inclusions, but no αINX immunoreac-
tivity. Five cases had features consistent with NIFID, with neuronal inclusions positive for both FUS and αINX. 
Striatal atrophy was present in only two of the NIFID cases. Two cases had αINX-positive neuronal inclusions 
consistent with NIFID, but both lacked striatal atrophy and FUS immunoreactivity. Surprisingly, one of these 
two NIFID cases had lesions immunoreactive for TDP-43. 
Discussion: While FUS pathology remains a prominent feature of aFTLD-U, there is pathologic heterogeneity, 
including rare cases of NIFID with TDP-43- rather than FUS-positive inclusions. 
Keywords: FUS, TDP-43, Atypical frontotemporal lobar degeneration, NIFID, Electron microscope 
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Introduction 
The pathological term frontotemporal lobar de-
generation (FTLD) assumes the presence of focal frontal 
and anterior temporal lobar atrophy(1). Histologically, 
the majority of FTLDs are pathologically classified into 
two broad categories of tau-positive FTLD (FTLD-tau) 
and TDP-43-positive FTLD (FTLD-TDP) based on the pres-
ence of tau and TDP-43 immunoreactive inclusions, 
respectively(2, 3). A subset of FTLD cases however, lack 
tau and TDP-43 immunoreactivity, and instead have 
neuronal inclusions that are immunoreactive to ubiqui-
tin(4). Such cases have been referred to in the literature 
as atypical FTLD with ubiquitin inclusion (aFTLD-U)(5). In 
the past decade, immunohistochemical studies have 
revealed that the ubiquitinated protein in cases of 
aFTLD-U is the fused in sarcoma (FUS) protein(6). Inter-
estingly, there are two other relatively rare FTLD patho-
logical variants that also have neuronal inclusions that 
are immunoreactive to FUS(7, 8). These include the 
entity neuronal intermediate filament inclusion disease 
(NIFID)(9), previously known as neurofilament inclusion 
body disease(10), and basophilic inclusion body dis-
ease(11) that have also been referred to as the general-
ized variant of Pick’s disease(12). As a result, aFTLD-U, 
NIFID and basophilic inclusion body disease are all cur-
rently classified as subtypes of FTLD-FUS(3, 13). 
In keeping with pathologically lumping these three 
entities as FTLD-FUS, is the fact that all three subtypes of 
FTLD-FUS, particularly aFTLD-U and NIFID, are strongly 
associated with a clinical presentation of the behavioral 
variant of frontotemporal dementia (bvFTD)(13-15). 
Basophilic inclusion body disease is more strongly asso-
ciated with the juvenile form of amyotrophic lateral 
sclerosis(16). In addition, aFTLD-U and NIFID have both 
been found to be associated with striatal atrophy on 
MRI(17, 18). Hence, aFTLD-U and NIFID have a lot of 
features in common. One study has directly compared 
aFTLD-U and NIFID(19). Hence, little is known about 
which clinical and pathologically differences between 
the two variants may further help to distinguish them, 
and whether all cases of aFTLD-U and NIFID do indeed 
show FUS immunoreactivity. In this study, we set out to 
address these two unknowns in a cohort of 15 FTLD 
cases that including aFTLD (n=8) and NIFID (n=7). 
Materials and methods 
Subject selection 
The neuropathological databases at the Mayo Clin-
ic, Jacksonville, Florida were queried to identify all cases 
of FTLD that had been given a pathological diagnosis of 
NIFID or aFTLD-U. A total of 15 cases were identified. All 
15 cases were evaluated by a single expert neuropa-
thologist (DWD). 
Clinical data 
The medical records of all 15 cases were reviewed 
by one clinician with expertise in neurodegenerative 
diseases (KAJ) to abstract demographic and clinical in-
formation. Data abstracted included sex, age at onset, 
prominent symptoms during the disease course, family 
history of any neurodegenerative diseases and final 
clinical diagnosis prior to death. 
Pathological methods 
All 15 cases underwent histologic and ultrastruc-
tural evaluation. Tissue sections were stained with he-
matoxylin and eosin, Luxol fast blue-periodic acid Schiff 
(LFB-PAS) and Bielschowsky silver stains. Immunohisto-
chemical staining was performed using standard meth-
ods. The deparaffinized and rehydrated sections were 
steamed in distilled water for 30 min and im-
munostained in batches to assure consistency with a 
DAKO Autostainer (DAKO, Carpinteria, CA) using 3, 
3’diaminobenzidine as the chromogen. After im-
munostaining, the sections were lightly counterstained 
with hematoxylin. The following antibodies were used: 
phosphorylated neurofilament (SMI-31, 1:20,000; Co-
vance, Berkeley, CA); ubiquitin (mouse monoclonal Ubi-
1, 1:40,000; EnCor Biotechnology, Alachua, FL; rabbit 
polyclonal UBQ(20), 1:500 and rabbit polyclonal UH-
19(21), 1:2,500); phospho-tau (CP13, 1:100; Peter Da-
vies, Albert Einstein College of Medicine, Bronx, NY); 
alpha-synuclein (NACP(22), 1:3,000), alpha-internexin 
(1:100; EnCor Biotechnology, Alachua, FL); TDP-43 
(MC2085, Dr. Petrucelli, 1:1500), pTDP-43 (S409/410, 
Cosmo Bio Co., 1:5000) and rabbit polyclonal anti-FUS 
(1:500; HPA008784; Sigma, St. Louis. MO and Bethyl Lab; 
A300-302A; Montgomery, TX). The Sigma antibody gave 
consistent and better staining and was used throughout 
the study. The presence or absence of motor neuron 
disease was assessed and defined as previously de-
scribed, including stains for activated microglia(23). 
Electron microscopy 
Small pieces of formalin-fixed brains were im-
mersed in 2.5% glutaraldehyde-0.1 M cacodylate buffer 
overnight at 4ºC. After washing in buffer, they were 
post-fixed in aqueous 2% osmium tetroxide for 1 hr, 
washed and fixed in 1% uranyl acetate-50% ethanol for 
30 min, followed by dehydration in 70%, 80%, 95%, 
100% ethanols and propylene oxide. They were infiltrat-
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ed and embedded in Epon 812. Thin sections were 
stained with uranyl acetate and lead citrate and exam-
ined in a Philips 208S electron microscope fitted with a 
bottom-mount CCD camera (Orius 831, Gatan, 
Pleasanton, CA). 
Immunoelectron microscopy 
Small pieces of formalin-fixed brains were dehy-
drated in serial washes of 30%, 50%, 70%, 90% ethanol 
for 10 min each, infiltrated and embedded in LR White 
resin. They were polymerized in a vacuum oven at 50oC 
for 2 days. Thin sections were collected on Formvar-
coated nickel grids.  Grids were floated with section-
sides down on citrate buffer, pH 6.0, in a 100oC oven for 
10 min, cooled to room temperature for 15 min followed 
by immunogold labeling. The Sigma anti-FUS was used at 
1:20 in PBS. 
Results 
Demographics and clinical data for all 15 cases are 
shown in Table 1. There were 10 males and 5 females 
with median age at death of 54 years (range 41-69 
years). The median disease duration was 5 years (range 
3-13 years). The most common final clinical diagnosis in 
this series was behavioral variant of frontotemporal 
dementia (bvFTD)(4, 24), rendered in 10 (67%) cases. 
 
Table 1: Demographic and clinical features of all 15 cases 
Case Sex Age/ death Duration Prominent symptoms/signs Diagnosis 
NIFID1‡ F 54 4 Behavioral & executive changes, mute bvFTD 
NIFID2* M 51 5 Falls, pyramidal & extrapyramidal PLS 
NIFID3 F 50 4 Behavioral change, OCB, hyper-religious bvFTD 
NIFID4 M 49 3 Apraxic dysgraphia, exacerbated startle, pyramidal and extrapyramidal signs CBS 
NIFID5 M 67 3 Falls, stiffness, difficult walking, speech apraxia, myo-clonic arm jerks, bradykinesia MSA-P 
NIFID6 M 41 4 Personality change, easily distractible, OCD-like behav-iors, disinhibited bvFTD 
NIFID7 F 61 2 Dynamic aphasia, later mute, difficulty walking, swal-lowing. Non-ambulatory PSP 
aFTLD-U1† M 68 5 Aphasia, apraxia, extrapyramidal CBS 
aFTLD-U2† M 42 4 Personality change, hypersexual, hyperphagic bvFTD 
aFTLD-U3 F 42 10 Personality change, hypersexual, mute (could sing) bvFTD 
aFTLD-U4† M 53 10 Personality change, hallucinations, insomnia, hyper-phagic, stereotypy bvFTD 
aFTLD-U5 M 69 5 Behavioral change with lack of initiative, more placid bvFTD 
aFTLD-U6 M 58 11 Personality change, mute, hypersexual, docile, hyper-phagic, poor hygiene, hyper oral bvFTD 
aFTLD-U7 F 55 5 Personality change, poor hygiene, socially withdrawn bvFTD 
aFTLD-U8 M 45 13 Personality change, disorganized behavior, increased appetite bvFTD 
ALS = amyotrophic lateral sclerosis; bvFTD = behavioral variant frontotemporal dementia; CBS = corticobasal syndrome 
OCB = obsessive compulsive behavior; PSP = progressive supranuclear palsy, SND = striatonigral degeneration 
† Previously published (Josephs et al. Acta Neuropathol 2008; 116: 159-167) 
‡ Previously published (Josephs et al. Brain 2003; 126: 2291-2303 
* Previously published (Josephs et al. Acta Neuropathol 2005; 109: 427-32) 
Free Neuropathology 1:9 (2020) Kevin F. Bieniek et al 
doi: https://doi.org/10.17879/freeneuropathology-2020-2639 page 4 of 10 
 
 
 
For the other 5 cases, the final clinical diagnoses 
were corticobasal syndrome in two cases(25), and one 
each diagnosed with progressive supranuclear palsy(26), 
primary lateral sclerosis(27) and multiple system atro-
phy-Parkinsonian type (MSA-P)(28). 
The median age of onset of the NIFID cases was 52 
years old (range: 41-61 years) while for aFTLD-U it was 
54 years old (range: 42-69 years). Disease duration in 
NIFID was only 3.5 years (range: 2.0-5.0 years) and was 
much shorter than the median disease duration of the 
aFTLD-U group which was 10 years (range: 4-13 years) 
(P<0.05). The clinical diagnoses were heterogeneous in 
the NIFID cases, with three cases (43%) diagnosed as 
bvFTD. On the other hand, of the aFTLD-U cases all but 
one (88%) had been diagnosed with bvFTD. The NIFID 
cases were more likely to have had pyramidal tract signs 
and motor dysfunction compared to the aFTLD-U cases; 
myoclonic jerks and excessive startle were also observed 
in NIFID but not aFTLD-U. 
Pathological findings 
Gross examination 
All 15 cases had evidence of frontal and temporal 
lobe atrophy, and hence all met criteria for FTLD. Striatal 
atrophy was observed in nine of the 15 cases (Table 2, 
Figure 1). 
Light microscopy 
Results of the light microscopic examination are 
shown in Table 2 and Figure 2. None of the 15 cases had 
evidence of tau deposition, and none met criteria for 
Alzheimer’s or Lewy body disease. All 15 cases were 
immune-reactive to ubiquitin. Thirteen of the 15 cases 
had neuronal inclusions that were immune-reactive to 
FUS. Seven of the 15 cases had eosinophilic inclusions 
that were seen on hematoxylin and eosin and were 
immunostained for α-internexin in keeping with their 
pathological diagnosis of NIFID. None of the remaining 
eight cases that had been diagnosed as aFTLD-U showed 
α-internexin immunoreactivity. Seven of the eight 
aFTLD-U cases (88%) showed severe striatal atrophy 
with FUS-positive neuronal cytoplasmic and vermiform 
intranuclear inclusions. Of the seven NIFID cases, five 
cases had neuronal inclusions that were immunoreactive 
to FUS. Unlike in aFTLD-U, striatal atrophy was only pre-
sent in only 2/7 (29%) of the NIFID cases, both of which 
were FUS positive. Hence, neither of the two FUS nega-
tive NIFID cases had striatal atrophy. Therefore, 9/13 
cases with FUS immunoreactive inclusions showed stria-
tal atrophy while 0/2 without FUS showed striatal atro-
phy. Surprisingly, one of the two NIFID cases without 
FUS immunoreactivity had lesions that were immunore-
active for both α-internexin and TDP-43 (Figure 3). 
 
Table 2: NCI immunohistochemical profile in 15 aFTLD-U and NIFID cases 
Case H&E Ubiquitin α-internexin TDP-43 FUS (NII) Striatal Atrophy 
NIFID1 + + + - + (NA) - 
NIFID2 + + + - + (NA) - 
NIFID3 + + + + - (NA) - 
NIFID4 + + + - - (NA) - 
NIFID5 + + + - +/- (NA) - 
NIFID6 + + + - + (NA) + 
NIFID7 + + + - + (NA) + 
aFTLD-U1 + + - - + (+) + 
aFTDL-U2 - + - - + (+) + 
aFTLD-U3 - + - - + (+) + 
aFTLD-U4 - + - - + (+) + 
aFTLD-U5 - + - - + (+) + 
aFTLD-U6β - + - - + (+) + 
aFTLD-U7 - + - - + (+) - 
aFTLD-U8 - + - - + (+) + 
β Diffuse cytoplasmic FUS staining with mini-Pick body-like NCI 
NA = not able to find any neuronal intranuclear inclusions (NII) 
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Figure 1: Striatal atrophy on gross examination 
 
Striatal atrophy was not seen in many NIFID cases (A; Case 5) and was only observed in two cases (B; Case 6). Conversely, only one 
aFTLD-U case lacked marked striatal atrophy (C; Case 14) while the rest of the aFTLD-U cases demonstrated severe atrophy (D; Case 13) 
[bar: 1 cm]. 
 
 
Figure 2: Alpha-internexin and FUS pathology 
 
Hematoxylin and Eosin (A/E/I/M), α-internexin (B/F/J/N) and FUS (C/G/K/O) in the frontal cortex and FUS (D/H/L/P) in the hippocampus 
of Cases 4 (A-D), 5 (E-H), 7 (I-L), and 15 (M-P) [bar:100 μm] 
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Figure 3:  FUS negative TDP-43 positive NIFID case 
 
Neuronal eosinophilic (A/B) inclusions in the hippocampus (A/C/E/G) and frontal cortex (B/D/F/H) of Case 3 are negative for FUS (C/D) 
but positive for TDP-43 (E/F/H), as well as αINX (G/H). α-internexin (brown) and TDP-43 (blue) colocalizes on double-labeling immuno-
histochemistry (H)[bar:100 μm] 
 
 
Electron and immunoelectron microscopy 
Results of the electron microscopic examination 
are shown in Figure 4. In the FUS-positive NIFID cases, 
we found that FUS was localized to loose granulofila-
ments that were in close proximity to intermediate fila-
ment inclusions that contained tightly packed uncoated 
filaments unlabeled by FUS antibody. The two types of 
filaments did not mix. The compact intermediate fila-
ment inclusions were similar to those we previously 
reported(29). In the TDP-positive NIFID case (#3), the 
TDP-positive NCIs were composed of granulofilaments in 
tightly packed bundles or loose orientations. Cytoplas-
mic organelles, e.g. mitochondria, were occasionally 
encompassed by these inclusions. 
These granulofilaments were not labeled with FUS. 
The characteristic compact intermediate filament inclu-
sions were not as widespread as the TDP-positive inclu-
sions in this case. Importantly, they were located in 
separate neurons. In addition to their ultrastructural 
difference from the TDP-positive inclusions, these in-
termediate filament inclusions were not labeled by TDP-
43. Immunohistochemistry showed that the intermedi-
ate filament inclusions were immuno-negative for FUS. 
The TDP-negative, FUS-negative NIFID case (#4) had 
compact intermediate filament inclusions similar to 
those described above. These compact intermediate 
filament inclusions were immuno-negative to FUS and 
TDP-43. Neuronal cytoplasmic inclusions in all the 
aFTLD-U cases consisted of granulofilaments inclusions 
in loose arrangement and all were immuno-positive for 
FUS. 
Discussion 
In this study we found pathological evidence for 
aFTLD-U to be a homogeneous entity that is strongly 
associated with a clinical diagnosis of bvFTD, and patho-
logically by FUS immunoreactivity and striatal atrophy. 
On the other hand, we found NIFID to be more hetero-
geneous with more variable clinical presentations. Fur-
thermore, NIFID does not always appear to be associat-
ed with FUS immunoreactivity and is typically not asso-
ciated with striatal atrophy. Interestingly, we found 
evidence of overlap between a case that would meet 
criteria for FTLD-TDP as well as NIFID. 
In this study, aFTLD-U was a very homogeneous 
entity and the evidence supports aFTLD-U being classi-
fied as FTLD-FUS. From a clinical standpoint aFTLD-U is 
strongly associated with clinical features of bvFTD as 
previously reported(14, 30) and hence should be consid-
ered in patients presenting with bvFTD especially in the 
presence of striatal atrophy. Indeed striatal atrophy has 
been reported in aFTLD-U on antemortem MRI imag-
ing(17). NIFID, on the other hand, as currently defined 
does not appear to be as distinct an entity clinically and 
pathologically as aFTLD-U. Supportive of this statement 
is the fact that of the seven NIFID cases in 
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Figure 4: Electron Microscopy 
 
Variable α-internexin (A/D/G), FUS (B/E/H), and TDP-43 (C/F/I) immunoreactivity on electron microscopy in the neuronal inclusions of 
Cases 3 (A-C), 2 (D-F), and 9 (G-I)[bar: 2 μm main; 0.3 μm inset] 
 
 
this study, patients were given five different clinical 
diagnoses at the last evaluation prior to death. Secondly, 
striatal atrophy, although present in two NIFID case was 
absent in the rest. Interestingly, both NIFID cases with 
striatal atrophy showed FUS immunoreactivity, one with 
a clinical diagnosis of bvFTD. It therefore appears that 
striatal atrophy is predictive of FUS, but FUS is not nec-
essarily predictive of striatal atrophy. Regardless, NIFID 
should also be considered in the differential diagnosis of 
bvFTD with striatal atrophy and should suggest the pres-
ence of FTLD-FUS. The one feature that may be helpful 
in predicting FTLD-FUS NIFID from FTLD-FUS aFTLD-U in 
patients with bvFTD and striatal atrophy may be the 
rapidity of progression, with faster progression being 
more suggestive of FTLD-FUS NIFID. 
To understand what may be happening with NIFID 
it is worth further discussion. Neuronal intermediate 
filament inclusion body disease is a type of FTLD with 
previously reported clinical presenting features of 
bvFTD, corticobasal syndrome, and motor neuron dis-
ease, especially the primary lateral sclerosis variant(10, 
31, 32). Typically, patients with NIFID have a relatively 
rapidly progressive course, becoming mute and unable 
to ambulate, dying around 3 ½ years after onset(10). 
These features were observed in this cohort of seven 
NIFID cases. From a pathological standpoint, in NIFID, 
neuronal cytoplasmic inclusions (NCIs) are easily visible 
on hematoxylin and eosin, show variable staining to 
ubiquitin and silver stains but are strikingly immunoreac-
tive to type IV intermediate filaments, including neuro-
filament and α-internexin(9, 10, 33, 34). These NCI, 
however, are not morphologically homogeneous and it 
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has been known from the original description of 
NIFID(10) that NCI appeared to separate into two types: 
rounded inclusions that are similar to Pick bodies, hence 
called ‘Pick-body like (PBL) inclusions,’ and smaller more 
compact inclusions with a glass like appearance called 
‘compact hyaline inclusions’(7, 10, 19, 29). Could this NCI 
inclusion type difference be playing any role in the het-
erogeneity we observed in this study? The ultrastructual 
analysis in our seven NIFID cases shows that these two 
different types of NCI also have different ultrastructual 
appearances. The PBL inclusions were ultrastructually 
granulofilamentous while the compact hyaline inclusions 
had a more tightly compact appearance. With immunoe-
lectron microscopy we found that the granulofilamen-
tous inclusions were immunoreactive to FUS while the 
compact hyaline inclusions were immunoreactive to 
intermediate filament. Interestingly all seven NIFID cases 
had compact hyaline inclusions, and all seven showed α-
internexin immunoreactivity. However, unlike in previ-
ous reports(35, 36), two of our seven NIFID cases did not 
show FUS immunoreactivity and one of these two NIFID 
cases showed predominantly, almost exclusively, com-
pact hyaline inclusions (Case #4). This NIFID case was 
immuno-negative to FUS, suggesting that the absence of 
the granulofilamentous inclusions may be the explana-
tion for the absence of FUS immunoreactivity. The other 
FUS negative case (Case #3) is also unique. In this case, 
both granulofilamentous inclusions and compact hyaline 
inclusions were present. As expected, the presence of 
the compact hyaline inclusions was associated with α-
internexin immunoreactivity. Surprisingly though, the 
granulofilamentous inclusions in this case (Case #3) 
showed immunoreactivity to TDP-43 but not FUS. It is 
therefore possible that this is a case of FTLD-TDP in 
which compact hyaline inclusions happen to also be 
present and hence accounts for the α-internexin immu-
noreactivity observed. This would not be counterintui-
tive since granulofilamentous morphology is the typical 
appearance of the NCIs in FTLD-TDP(37). On the other 
hand, we cannot exclude the possibility that this is a 
case of NIFID with TDP-43 immunoreactivity given that 
TDP-43 immunoreactivity has been described in many 
different diseases(38). 
Compared to our NIFID cases, all eight aFTLD-U 
cases showed a homogeneous pattern of FUS immuno-
reactivity similar to what has been previously report-
ed(6, 8, 19, 36). In our eight aFTLD-U cases, ultrastruc-
tural analysis demonstrated granulofilamentous inclu-
sions as we previously reported(4), and immunoelectron 
microscopy revealed FUS immunoreactivity. Of note is 
the fact that compact hyaline inclusions were absent in 
all eight aFTLD-U cases. This finding would also support 
our hypothesis that FUS immunoreactivity in NIFID and 
aFTLD-U is associated with the presence of the granu-
lofilamentous inclusions while α-internexin immunore-
activity is associated with the presence of the compact 
hyaline inclusions. It remains unclear however; why 
some granulofilamentous inclusions show exclusive FUS 
immunoreactivity (e.g. aFTLD-U) and others show exclu-
sive TDP-43 immunoreactivity (e.g. FTLD-TDP). Only one 
study to date has reported both FUS and TDP-43 immu-
noreactivity in the same NCIs(39). 
Overall, the data from this study support the im-
portance of FUS in the pathogenesis of aFTLD-U and the 
classification of aFTLD-U as an FTLD-FUS. However, the 
role of FUS in NIFID is less clear, with evidence support-
ing NIFID being somewhat different from aFTLD-U with a 
concern that NIFID, at least not all cases, may be incor-
rectly classified as a subtype of FTLD-FUS. Supporting 
this statement is the fact that another FUS negative case 
with α-internexin positive inclusions has been de-
scribed(40). In this other case, however, a SOD1 muta-
tion was identified and some inclusions were immuno-
reactive to SOD1. On a different note, the presence of 
intermediate filament inclusions and TDP-43 immunore-
active inclusions in the same case makes one contem-
plate the current sub-classification of FTLD into strict 
categories. The relationship between FUS and interme-
diate filament is reminiscent of the relationship between 
Alzheimer’s disease pathology and Lewy body disease. 
Alzheimer’s disease pathology can occur in isolation, as 
can Lewy body disease, but there are instances in which 
both Alzheimer’s disease and Lewy body disease co-
occur. It would be naïve to argue that when two pathol-
ogies co-occur, that one pathology is more important or 
more relevant than the other. 
In summary, aFTLD-U and NIFID share some but 
not all features. Striatal atrophy, while appearing to be a 
characteristic feature of aFTLD-U, does not appear to be 
a feature of NIFID although it can occur in some cases. 
Further analyses are needed to better understand the 
relationship of aFTLD-U to NIFID and of NIFID to FUS. 
Such analysis should include the assessment of other 
proteins that have been reported to be associated with 
aFTLD-U and NIFID including TAF15 and EWS(41), as well 
as transportin1(42). 
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